{"protocolSection":{"identificationModule":{"nctId":"NCT03117049","orgStudyIdInfo":{"id":"ONO-4538-52"},"organization":{"fullName":"Ono Pharmaceutical Co. Ltd","class":"INDUSTRY"},"briefTitle":"Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)","officialTitle":"A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)"},"statusModule":{"statusVerifiedDate":"2024-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-06-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-02-10","type":"ACTUAL"},"completionDateStruct":{"date":"2023-12-04","type":"ACTUAL"},"studyFirstSubmitDate":"2017-04-12","studyFirstSubmitQcDate":"2017-04-14","studyFirstPostDateStruct":{"date":"2017-04-17","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-10-21","resultsFirstSubmitQcDate":"2022-04-25","resultsFirstPostDateStruct":{"date":"2022-04-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-05-02","lastUpdatePostDateStruct":{"date":"2024-05-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ono Pharmaceutical Co. Ltd","class":"INDUSTRY"},"collaborators":[{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-naïve subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation in a multicenter, randomized, double-blind study."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":550,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"ONO-4538 group","type":"EXPERIMENTAL","description":"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.","interventionNames":["Drug: ONO-4538","Drug: Carboplatin","Drug: Paclitaxel","Drug: Bevacizumab"]},{"label":"Placebo group","type":"PLACEBO_COMPARATOR","description":"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.","interventionNames":["Drug: Carboplatin","Drug: Paclitaxel","Drug: Bevacizumab","Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"ONO-4538","description":"360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.","armGroupLabels":["ONO-4538 group"]},{"type":"DRUG","name":"Carboplatin","description":"Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.","armGroupLabels":["ONO-4538 group","Placebo group"]},{"type":"DRUG","name":"Paclitaxel","description":"Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.","armGroupLabels":["ONO-4538 group","Placebo group"]},{"type":"DRUG","name":"Bevacizumab","description":"Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.","armGroupLabels":["ONO-4538 group","Placebo group"]},{"type":"DRUG","name":"Placebo","description":"Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.","armGroupLabels":["Placebo group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC)","description":"PFS (as assessed by the IRRC) will be calculated using the following formula : PFS (days) = \"date when overall response is assessed as progressive disease (PD) or date of death (for any reason), whichever comes first\" - \"date of randomization\" + 1. Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.","timeFrame":"Approximately 32 months"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Approximately 32 months"},{"measure":"Objective Response Rate (ORR [as Assessed by the IRRC])","description":"ORR represents the proportion of subjects whose best overall response was assessed as complete response (CR) or partial response (PR). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.","timeFrame":"Approximately 32 months"},{"measure":"Disease Control Rate (DCR [as Assessed by the IRRC])","description":"DCR represents the proportion of subjects whose best overall response was assessed as CR, PR, or stable disease (SD). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.","timeFrame":"Approximately 32 months"},{"measure":"Duration of Response (DOR [as Assessed by the IRRC])","description":"The lower and upper limits of 95% CI for the median are censored value in the both groups.","timeFrame":"Approximately 32 months"},{"measure":"Best Overall Response (BOR [as Assessed by the IRRC])","timeFrame":"Approximately 32 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with histologically- or cytologically-confirmed non-squamous non-small cell lung cancer\n* Subjects who received a diagnosis of stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation according to the UICC-TNM Classification (7th edition) with no prior systemic anticancer therapy\n* Subjects with at least one measurable lesion by radiographic tumor assessments per RECIST 1.1 criteria\n* Subjects who are able to provide tumor tissue specimens.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1\n\nExclusion Criteria:\n\n* Subjects with known EGFR mutations, including deletions in exon 19 and exon 21 (L858R) substitution mutations.\n* Subjects with known ALK translocations.\n* Complication or history of severe hypersensitivity reactions to antibody products or platinum-containing compounds\n* Subjects with autoimmune disease or known chronic or recurrent autoimmune disease.\n* Subjects with multiple cancer.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Shigeru Takahashi","affiliation":"Ono Pharmaceutical Co. Ltd","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Aichi Clinical Site2","city":"Nagoya","state":"Aichi-ken","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Aichi Clinical Site3","city":"Nagoya","state":"Aichi-ken","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Aichi Clinical Site4","city":"Nagoya","state":"Aichi-ken","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Aichi Clinical Site","city":"Nagoya","state":"Aichi-ken","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Aichi Clinical Site","city":"Toyoake","state":"Aichi-ken","country":"Japan","geoPoint":{"lat":35.038,"lon":136.99931}},{"facility":"Aomori Clinical Site2","city":"Hirosaki","state":"Aomori","country":"Japan","geoPoint":{"lat":40.59306,"lon":140.4725}},{"facility":"Aomori Clinical Site","city":"Hirosaki","state":"Aomori","country":"Japan","geoPoint":{"lat":40.59306,"lon":140.4725}},{"facility":"Chiba Clinical Site","city":"Yachiyo","state":"Chiba","country":"Japan","geoPoint":{"lat":35.73531,"lon":140.12445}},{"facility":"Ehime Clinical Site","city":"Matsuyama","state":"Ehime","country":"Japan","geoPoint":{"lat":33.83916,"lon":132.76574}},{"facility":"Fukuoka Clinical Site","city":"Iizuka","state":"Fukuoka","country":"Japan","geoPoint":{"lat":33.63654,"lon":130.68678}},{"facility":"Fukuoka Clinical Site","city":"Kitakyushu","state":"Fukuoka","country":"Japan","geoPoint":{"lat":33.85181,"lon":130.85034}},{"facility":"Fukuoka Clinical Site","city":"Koga","state":"Fukuoka","country":"Japan","geoPoint":{"lat":33.73333,"lon":130.46667}},{"facility":"Fukuoka Clinical Site","city":"Kurume","state":"Fukuoka","country":"Japan","geoPoint":{"lat":33.31667,"lon":130.51667}},{"facility":"Fukushima Clinical Site","city":"Kōriyama","state":"Fukushima","country":"Japan","geoPoint":{"lat":37.4,"lon":140.38333}},{"facility":"Gunma Clinical Site","city":"Ōta","state":"Gunma","country":"Japan","geoPoint":{"lat":36.3,"lon":139.36667}},{"facility":"Gunma Clinical Site","city":"Shibukawa","state":"Gunma","country":"Japan","geoPoint":{"lat":36.48333,"lon":139.0}},{"facility":"Hokkaido Clinical Site","city":"Asahikawa","state":"Hokkaido","country":"Japan","geoPoint":{"lat":43.77063,"lon":142.36489}},{"facility":"Hokkaido Clinical Site2","city":"Sapporo","state":"Hokkaido","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Hokkaido Clinical Site","city":"Sapporo","state":"Hokkaido","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Hyogo Clinical Site","city":"Akashi","state":"Hyōgo","country":"Japan","geoPoint":{"lat":34.65524,"lon":135.00687}},{"facility":"Hyogo Clinical Site","city":"Amagasaki","state":"Hyōgo","country":"Japan","geoPoint":{"lat":34.71667,"lon":135.41667}},{"facility":"Hyogo Clinical Site","city":"Himeji","state":"Hyōgo","country":"Japan","geoPoint":{"lat":34.81667,"lon":134.7}},{"facility":"Hyogo Clinical Site","city":"Itami","state":"Hyōgo","country":"Japan","geoPoint":{"lat":34.78427,"lon":135.40126}},{"facility":"Hyogo Clinical Site","city":"Kobe","state":"Hyōgo","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Hyogo Clinical Site","city":"Nishinomiya","state":"Hyōgo","country":"Japan","geoPoint":{"lat":34.71562,"lon":135.33199}},{"facility":"Hyogo Clinical Site","city":"Takarazuka","state":"Hyōgo","country":"Japan","geoPoint":{"lat":34.79936,"lon":135.35697}},{"facility":"Ibaraki Clinical Site","city":"Higashiibaraki","state":"Ibaraki","country":"Japan"},{"facility":"Ibaraki Clinical Site","city":"Kasama","state":"Ibaraki","country":"Japan","geoPoint":{"lat":36.38333,"lon":140.26667}},{"facility":"Ibaraki Clinical Site","city":"Tsuchiura","state":"Ibaraki","country":"Japan","geoPoint":{"lat":36.09047,"lon":140.21047}},{"facility":"Ishikawa Clinical Site2","city":"Kanazawa","state":"Ishikawa-ken","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Ishikawa Clinical Site3","city":"Kanazawa","state":"Ishikawa-ken","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Ishikawa Clinical Site","city":"Kanazawa","state":"Ishikawa-ken","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Iwate Clinical Site","city":"Morioka","state":"Iwate","country":"Japan","geoPoint":{"lat":39.7,"lon":141.15}},{"facility":"Kanagawa Clinical Site","city":"Isehara","state":"Kanagawa","country":"Japan","geoPoint":{"lat":35.39932,"lon":139.31019}},{"facility":"Kanagawa Clinical Site2","city":"Kawasaki","state":"Kanagawa","country":"Japan","geoPoint":{"lat":35.52056,"lon":139.71722}},{"facility":"Kanagawa Clinical Site","city":"Kawasaki","state":"Kanagawa","country":"Japan","geoPoint":{"lat":35.52056,"lon":139.71722}},{"facility":"Kanagawa Clinical Site","city":"Sagamihara","state":"Kanagawa","country":"Japan","geoPoint":{"lat":35.56707,"lon":139.24167}},{"facility":"Kanagawa Clinical Site2","city":"Yokohama","state":"Kanagawa","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Kanagawa Clinical Site3","city":"Yokohama","state":"Kanagawa","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Kanagawa Clinical Site","city":"Yokohama","state":"Kanagawa","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Kumamoto Clinical Site","city":"Kōshi","state":"Kumamoto","country":"Japan","geoPoint":{"lat":32.89271,"lon":130.77567}},{"facility":"Kyoto Clinical Site","city":"Jōyō","state":"Kyoto","country":"Japan","geoPoint":{"lat":34.84396,"lon":135.80561}},{"facility":"Mie Clinical Site","city":"Tsu","state":"Mie-ken","country":"Japan","geoPoint":{"lat":34.73333,"lon":136.51667}},{"facility":"Miyagi Clinical Site","city":"Natori-shi","state":"Miyagi","country":"Japan","geoPoint":{"lat":38.16667,"lon":140.88333}},{"facility":"Miyagi Clinical Site","city":"Sendai","state":"Miyagi","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Nagano Clinical Site","city":"Matsumoto","state":"Nagano","country":"Japan","geoPoint":{"lat":36.23333,"lon":137.96667}},{"facility":"Nagasaki Clinical Site","city":"Ōmura","state":"Nagasaki","country":"Japan","geoPoint":{"lat":32.92139,"lon":129.95389}},{"facility":"Nara Clinical Site","city":"Ikoma","state":"Nara","country":"Japan","geoPoint":{"lat":34.68333,"lon":135.7}},{"facility":"Niigata Clinical Site","city":"Nagaoka","state":"Niigata","country":"Japan","geoPoint":{"lat":37.45,"lon":138.85}},{"facility":"Oita Clinical Site","city":"Beppu","state":"Oita Prefecture","country":"Japan","geoPoint":{"lat":33.27945,"lon":131.49751}},{"facility":"Oita Clinical Site","city":"Yufu","state":"Oita Prefecture","country":"Japan","geoPoint":{"lat":33.1956,"lon":131.37829}},{"facility":"Osaka Clinical Site","city":"Habikino","state":"Osaka","country":"Japan","geoPoint":{"lat":34.55276,"lon":135.59097}},{"facility":"Osaka Clinical Site","city":"Hirakata","state":"Osaka","country":"Japan","geoPoint":{"lat":34.81352,"lon":135.64914}},{"facility":"Osaka Clinical Site","city":"Kishiwada","state":"Osaka","country":"Japan","geoPoint":{"lat":34.46667,"lon":135.36667}},{"facility":"Osaka Clinical Site","city":"Sakai","state":"Osaka","country":"Japan","geoPoint":{"lat":34.58216,"lon":135.46653}},{"facility":"Osaka Clinical Site","city":"Sayama","state":"Osaka","country":"Japan","geoPoint":{"lat":34.51685,"lon":135.56298}},{"facility":"Osaka Clinical Site","city":"Toyonaka","state":"Osaka","country":"Japan","geoPoint":{"lat":34.78244,"lon":135.46932}},{"facility":"Osaka Clinical Site2","city":"Osaka","state":"Osaka Clinical Site","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Saga Clinical Site","city":"Ureshino","state":"Saga-ken","country":"Japan","geoPoint":{"lat":33.13525,"lon":130.05718}},{"facility":"Saitama Clinical Site","city":"Hidaka","state":"Saitama","country":"Japan","geoPoint":{"lat":35.91664,"lon":139.36233}},{"facility":"Saitama Clinical Site","city":"Kitaadachi-gun","state":"Saitama","country":"Japan"},{"facility":"Shimane Clinical Site","city":"Izumo","state":"Shimane","country":"Japan","geoPoint":{"lat":35.36667,"lon":132.76667}},{"facility":"Shizuoka Clinical Site","city":"Hamamatsu","state":"Shizuoka","country":"Japan","geoPoint":{"lat":34.7,"lon":137.73333}},{"facility":"Shizuoka Clinical Site","city":"Sunto-gun","state":"Shizuoka","country":"Japan"},{"facility":"Tokyo Clinical Site2","city":"Bunkyo-ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site","city":"Bunkyo-ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site2","city":"Bunkyō-Ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site2","city":"Chuo-ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site","city":"Chuo-ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site","city":"Fuchū","state":"Tokyo","country":"Japan","geoPoint":{"lat":35.67452,"lon":139.48216}},{"facility":"Tokyo Clinical Site","city":"Itabashi-ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site","city":"Kiyose","state":"Tokyo","country":"Japan","geoPoint":{"lat":35.77952,"lon":139.53014}},{"facility":"Tokyo Clinical Site","city":"Koto-ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site","city":"Meguro City","state":"Tokyo","country":"Japan","geoPoint":{"lat":35.6322,"lon":139.70174}},{"facility":"Tokyo Clinical Site","city":"Minato-ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site","city":"Mitaka-shi","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site","city":"Shibuya City","state":"Tokyo","country":"Japan","geoPoint":{"lat":35.6589,"lon":139.70665}},{"facility":"Tokyo Clinical Site2","city":"Shinjuku-Ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site3","city":"Shinjuku-Ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site","city":"Shinjuku-ku","state":"Tokyo","country":"Japan"},{"facility":"Tokyo Clinical Site","city":"Tachikawa","state":"Tokyo","country":"Japan","geoPoint":{"lat":35.7091,"lon":139.41891}},{"facility":"Tottori Clinical Site","city":"Yonago","state":"Tottori","country":"Japan","geoPoint":{"lat":35.43333,"lon":133.33333}},{"facility":"Yamaguchi Clinical Site","city":"Iwakuni","state":"Yamaguchi","country":"Japan","geoPoint":{"lat":34.16297,"lon":132.22}},{"facility":"Chiba Clinical Site2","city":"Chiba","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"Chiba Clinical Site","city":"Chiba","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"Fukui Clinical Site","city":"Fukui","country":"Japan","geoPoint":{"lat":34.84214,"lon":135.54836}},{"facility":"Fukuoka Clinical Site2","city":"Fukuoka","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Fukuoka Clinical Site3","city":"Fukuoka","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Fukuoka Clinical Site4","city":"Fukuoka","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Fukuoka Clinical Site","city":"Fukuoka","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Gifu Clinical Site2","city":"Gifu","country":"Japan","geoPoint":{"lat":35.42291,"lon":136.76039}},{"facility":"Gifu Clinical Site","city":"Gifu","country":"Japan","geoPoint":{"lat":35.42291,"lon":136.76039}},{"facility":"Hiroshima Clinical Site2","city":"Hiroshima","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"Hiroshima Clinical Site","city":"Hiroshima","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"Kochi Clinical Site","city":"Kochi","country":"Japan","geoPoint":{"lat":33.55,"lon":133.53333}},{"facility":"Kumamoto Clinical Site","city":"Kumamoto","country":"Japan","geoPoint":{"lat":32.80589,"lon":130.69181}},{"facility":"Kyoto Clinical Site","city":"Kyoto","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"Nagasaki Clinical Site","city":"Nagasaki","country":"Japan","geoPoint":{"lat":32.75,"lon":129.88333}},{"facility":"Niigata Clinical Site2","city":"Niigata","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"Niigata Clinical Site","city":"Niigata","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"Okayama Clinical Site2","city":"Okayama","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Okayama Clinical Site","city":"Okayama","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Osaka Clinical Site3","city":"Osaka","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Osaka Clinical Site","city":"Osaka","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Oita Clinical Site","city":"Ōita","country":"Japan","geoPoint":{"lat":33.23333,"lon":131.6}},{"facility":"Tokushima Clinical Site","city":"Tokushima","country":"Japan","geoPoint":{"lat":34.06667,"lon":134.56667}},{"facility":"Toyama Clinical Site2","city":"Toyama","country":"Japan","geoPoint":{"lat":36.7,"lon":137.21667}},{"facility":"Toyama Clinical Site","city":"Toyama","country":"Japan","geoPoint":{"lat":36.7,"lon":137.21667}},{"facility":"Wakayama Clinical Site","city":"Wakayama","country":"Japan","geoPoint":{"lat":34.23333,"lon":135.16667}},{"facility":"Yamaguchi Clinical Site","city":"Yamaguchi","country":"Japan","geoPoint":{"lat":34.18333,"lon":131.46667}},{"facility":"Gangwon-Do Clinical Site","city":"Wŏnju","state":"Gangwon-do","country":"South Korea","geoPoint":{"lat":37.35139,"lon":127.94528}},{"facility":"Gyeonggi-do Clinical Site2","city":"Seongnam-si","state":"Gyeonggi-do","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Gyeonggi-do Clinical Site","city":"Seongnam-si","state":"Gyeonggi-do","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Gyeonggi-do Clinical Site","city":"Suwon","state":"Gyeonggi-do","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Gyeongsangnam-do Clinical Site","city":"Jinju","state":"Gyeongsangnam-do","country":"South Korea","geoPoint":{"lat":35.19278,"lon":128.08472}},{"facility":"Chungcheongbuk-do Clinical Site","city":"Cheongju-si","state":"North Chungcheong","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Busan Clinical Site","city":"Busan","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Daegu Clinical Site","city":"Daegu","country":"South Korea","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Incheon Clinical Site","city":"Incheon","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Seoul Clinical Site2","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Clinical Site3","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Clinical Site4","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Clinical Site5","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Clinical Site6","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Clinical Site","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Changhua Clinical Site","city":"Changhua","country":"Taiwan","geoPoint":{"lat":24.0692,"lon":120.5512}},{"facility":"Chiayi Clinical Site","city":"Chiayi City","country":"Taiwan","geoPoint":{"lat":23.47917,"lon":120.44889}},{"facility":"Kaohsiung Clinical Site2","city":"Kaohsiung City","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Kaohsiung Clinical Site3","city":"Kaohsiung City","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Kaohsiung Clinical Site","city":"Kaohsiung City","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Taichung Clinical Site","city":"Taichung","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Tainan Clinical Site","city":"Tainan","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Taipei Clinical Site2","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Taipei Clinical Site","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Taoyuan Clinical Site","city":"Taoyuan District","country":"Taiwan","geoPoint":{"lat":24.9896,"lon":121.3187}}]},"referencesModule":{"references":[{"pmid":"37641544","type":"DERIVED","citation":"Kim HR, Sugawara S, Lee JS, Kang JH, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K. First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial. Cancer Med. 2023 Aug;12(16):17061-17067. doi: 10.1002/cam4.6348. Epub 2023 Aug 28."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"ONO-4538 Group","description":"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."},{"id":"FG001","title":"Placebo Group","description":"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","comment":"Randomized","achievements":[{"groupId":"FG000","numSubjects":"275"},{"groupId":"FG001","numSubjects":"275"}]},{"type":"COMPLETED","comment":"Continued at least one study treatment at the time of cut-off","achievements":[{"groupId":"FG000","numSubjects":"74"},{"groupId":"FG001","numSubjects":"44"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"201"},{"groupId":"FG001","numSubjects":"231"}]}],"dropWithdraws":[{"type":"Continued the follow-up period","reasons":[{"groupId":"FG000","numSubjects":"109"},{"groupId":"FG001","numSubjects":"129"}]},{"type":"Died","reasons":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"93"}]},{"type":"Consent withdrawal","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Missing contact","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"ONO-4538 Group","description":"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."},{"id":"BG001","title":"Placebo Group","description":"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"275"},{"groupId":"BG001","value":"275"},{"groupId":"BG002","value":"550"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66","lowerLimit":"27","upperLimit":"85"},{"groupId":"BG001","value":"66","lowerLimit":"33","upperLimit":"83"},{"groupId":"BG002","value":"66","lowerLimit":"27","upperLimit":"85"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"<65 years","categories":[{"measurements":[{"groupId":"BG000","value":"131"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"242"}]}]},{"title":"65-74 years","categories":[{"measurements":[{"groupId":"BG000","value":"117"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"248"}]}]},{"title":">=75 years","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"60"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"139"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"205"},{"groupId":"BG001","value":"206"},{"groupId":"BG002","value":"411"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"275"},{"groupId":"BG001","value":"275"},{"groupId":"BG002","value":"550"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Country","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Japan","categories":[{"measurements":[{"groupId":"BG000","value":"188"},{"groupId":"BG001","value":"183"},{"groupId":"BG002","value":"371"}]}]},{"title":"Korea","categories":[{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"125"}]}]},{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"54"}]}]}]},{"title":"ECOG Performance Score","description":"Interactive Web Response System source. Score 0 : Fully active, able to carry on all pre-disease performance without restriction, Score 1 : Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work, office work","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"0","categories":[{"measurements":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"257"}]}]},{"title":"1","categories":[{"measurements":[{"groupId":"BG000","value":"146"},{"groupId":"BG001","value":"147"},{"groupId":"BG002","value":"293"}]}]}]},{"title":"Smoking status","description":"Former smokers included anyone who had smoked even a small quantity of any tobacco and had stopped smoking at the time of screening. Current smokers are anyone who had a smoking habit of any tobacco regardless of smoking duration/quantity at the screening.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Never","categories":[{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"115"}]}]},{"title":"Current","categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"39"}]}]},{"title":"Former","categories":[{"measurements":[{"groupId":"BG000","value":"196"},{"groupId":"BG001","value":"200"},{"groupId":"BG002","value":"396"}]}]}]},{"title":"Staging (the UICC-TNM classification, 7th edition)","description":"Stage IIIB:T4(Tumor of any size that invades the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, or with separate tumor nodules in a different ipsilateral lobe) and N2(Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)), or N3(Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)) with any T Stage IV:Distant metastasis","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Stage IIIB","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"29"}]}]},{"title":"Stage IV","categories":[{"measurements":[{"groupId":"BG000","value":"239"},{"groupId":"BG001","value":"238"},{"groupId":"BG002","value":"477"}]}]},{"title":"Recurrent","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"44"}]}]}]},{"title":"Metastasis","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Bone","categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"139"}]}]},{"title":"Liver","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"39"}]}]},{"title":"Brain","categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"77"}]}]}]},{"title":"PD-L1 expression levels","description":"Interactive Web Response System source. There were five patients with indeterminate PD-L1 expression levels in both arms.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"<1% or indeterminate","categories":[{"measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"120"},{"groupId":"BG002","value":"240"}]}]},{"title":"1%-49%","categories":[{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"163"}]}]},{"title":">=50","categories":[{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"147"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC)","description":"PFS (as assessed by the IRRC) will be calculated using the following formula : PFS (days) = \"date when overall response is assessed as progressive disease (PD) or date of death (for any reason), whichever comes first\" - \"date of randomization\" + 1. Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"96.37% Confidence Interval","unitOfMeasure":"months","timeFrame":"Approximately 32 months","groups":[{"id":"OG000","title":"ONO-4538 Group","description":"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Placebo Group","description":"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"275"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"9.8","upperLimit":"14.0"},{"groupId":"OG001","value":"8.1","lowerLimit":"7.0","upperLimit":"8.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.56","ciPctValue":"96.37","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.43","ciUpperLimit":"0.71"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Approximately 32 months","groups":[{"id":"OG000","title":"ONO-4538 Group","description":"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Placebo Group","description":"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"275"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","lowerLimit":"21.8","upperLimit":"NA","comment":"The Upper Limit has not been reached due to insufficient number of participants with events."},{"groupId":"OG001","value":"24.7","lowerLimit":"20.2","upperLimit":"NA","comment":"The Upper Limit has not been reached due to insufficient number of participants with events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Stratified hazard ratio","paramValue":"0.85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"1.14"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR [as Assessed by the IRRC])","description":"ORR represents the proportion of subjects whose best overall response was assessed as complete response (CR) or partial response (PR). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Approximately 32 months","groups":[{"id":"OG000","title":"ONO-4538 Group","description":"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Placebo Group","description":"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"275"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","lowerLimit":"55.4","upperLimit":"67.2"},{"groupId":"OG001","value":"50.5","lowerLimit":"44.5","upperLimit":"56.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"1.55","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.11","ciUpperLimit":"2.17"}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR [as Assessed by the IRRC])","description":"DCR represents the proportion of subjects whose best overall response was assessed as CR, PR, or stable disease (SD). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Approximately 32 months","groups":[{"id":"OG000","title":"ONO-4538 Group","description":"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Placebo Group","description":"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"275"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","lowerLimit":"82.7","upperLimit":"91.0"},{"groupId":"OG001","value":"89.8","lowerLimit":"85.6","upperLimit":"93.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"0.77","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.46","ciUpperLimit":"1.31"}]},{"type":"SECONDARY","title":"Duration of Response (DOR [as Assessed by the IRRC])","description":"The lower and upper limits of 95% CI for the median are censored value in the both groups.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Approximately 32 months","groups":[{"id":"OG000","title":"ONO-4538 Group","description":"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Placebo Group","description":"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"275"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"1.1","upperLimit":"25.8"},{"groupId":"OG001","value":"7.0","lowerLimit":"1.2","upperLimit":"26.0"}]}]}]},{"type":"SECONDARY","title":"Best Overall Response (BOR [as Assessed by the IRRC])","populationDescription":"For best overall response to be assessed as stable disease in this study, at least one stable disease or better rather than progressive disease on or after day 43 should be obtained.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Approximately 32 months","groups":[{"id":"OG000","title":"ONO-4538 Group","description":"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Placebo Group","description":"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"275"}]}],"classes":[{"title":"Complete response","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"8"}]}]},{"title":"Partial response","categories":[{"measurements":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"131"}]}]},{"title":"Stable disease","categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"108"}]}]},{"title":"Progressive disease","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"11"}]}]},{"title":"Not evaluable","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"17"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"For each randomised subject, adverse events(AEs) were collected from the start date of administration of the investigational product to 30 days after the last dose of any of the study treatment (The maximum was about 30 months). Drug-related AEs or AEs leading to discontinuation reported at the start of follow-up should be investigated at appropriate intervals until no further follow-up is required because the events have resolved or are resolving, or the symptoms become stable.","description":"All-Cause Mortality indicates the number of patients who died by any cause (e.g. Primary disease) from the start of the study to data cut off (approximately 32 months).\n\nOverall Number of Participants Analyzed in efficacy and All-cause Mortality is among ITT, whereas the risk population (AEs) is among SAF. Above is the reason of the gap b/w 275 and 273.\n\nITT: consist of all randomized subjects. SAF: consist of all subjects who received the investigational product or chemotherapy at least once.","eventGroups":[{"id":"EG000","title":"ONO-4538 Group","description":"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.","deathsNumAffected":82,"deathsNumAtRisk":275,"seriousNumAffected":154,"seriousNumAtRisk":273,"otherNumAffected":271,"otherNumAtRisk":273},{"id":"EG001","title":"Placebo Group","description":"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.\n\nChemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.","deathsNumAffected":93,"deathsNumAtRisk":275,"seriousNumAffected":118,"seriousNumAtRisk":275,"otherNumAffected":274,"otherNumAtRisk":275}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":273},{"groupId":"EG001","numAffected":12,"numAtRisk":275}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Splenic haemorrhage","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":2,"numAtRisk":275}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Cardiac ventricular thrombosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Adrenocorticotropic hormone deficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Hypopituitarism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Anal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Colitis microscopic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Diverticular perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Intra-abdominal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":2,"numAtRisk":275}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":3,"numAtRisk":275}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pancreatic fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Periodontal disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Rectal prolapse","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Small intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":3,"numAtRisk":275}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Haemorrhagic cyst","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":273},{"groupId":"EG001","numAffected":4,"numAtRisk":275}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Biloma","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Enteritis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Gastroenteritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Haematoma infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":2,"numAtRisk":275}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Large intestine infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Osteomyelitis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Otitis media chronic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pharyngotonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pleural infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":273},{"groupId":"EG001","numAffected":15,"numAtRisk":275}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pneumonia klebsiella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pseudomembranous colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pseudomonal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":3,"numAtRisk":275}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Post procedural fistula","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Vascular pseudoaneurysm","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Wound complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Angiocardiogram","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":273},{"groupId":"EG001","numAffected":8,"numAtRisk":275}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":2,"numAtRisk":275}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Fulminant type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Glucose tolerance impaired","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Tumour lysis syndrome","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Brain cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Gastric cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Gastrointestinal stromal tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Papillary thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Small intestine carcinoma metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Tumour haemorrhage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Brain stem infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":2,"numAtRisk":275}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":2,"numAtRisk":275}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Posterior reversible encephalopathy syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Postresuscitation encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Subarachnoid haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Acute interstitial pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":273},{"groupId":"EG001","numAffected":3,"numAtRisk":275}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":3,"numAtRisk":275}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":273},{"groupId":"EG001","numAffected":5,"numAtRisk":275}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Pulmonary thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Erythema multiforme","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Pemphigoid","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Skin burning sensation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Stevens-Johnson syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Toxic epidermal necrolysis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":273},{"groupId":"EG001","numAffected":2,"numAtRisk":275}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":88,"numAtRisk":273},{"groupId":"EG001","numAffected":102,"numAtRisk":275}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":273},{"groupId":"EG001","numAffected":15,"numAtRisk":275}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":273},{"groupId":"EG001","numAffected":19,"numAtRisk":275}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":273},{"groupId":"EG001","numAffected":38,"numAtRisk":275}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":273},{"groupId":"EG001","numAffected":21,"numAtRisk":275}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":273},{"groupId":"EG001","numAffected":5,"numAtRisk":275}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":273},{"groupId":"EG001","numAffected":4,"numAtRisk":275}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":273},{"groupId":"EG001","numAffected":8,"numAtRisk":275}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":6,"numAtRisk":275}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":4,"numAtRisk":275}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":273},{"groupId":"EG001","numAffected":11,"numAtRisk":275}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":273},{"groupId":"EG001","numAffected":8,"numAtRisk":275}]},{"term":"Cheilitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":273},{"groupId":"EG001","numAffected":2,"numAtRisk":275}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":150,"numAtRisk":273},{"groupId":"EG001","numAffected":134,"numAtRisk":275}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":273},{"groupId":"EG001","numAffected":2,"numAtRisk":275}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":81,"numAtRisk":273},{"groupId":"EG001","numAffected":66,"numAtRisk":275}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":273},{"groupId":"EG001","numAffected":13,"numAtRisk":275}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":273},{"groupId":"EG001","numAffected":3,"numAtRisk":275}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":273},{"groupId":"EG001","numAffected":8,"numAtRisk":275}]},{"term":"Gingival pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":273},{"groupId":"EG001","numAffected":6,"numAtRisk":275}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":10,"numAtRisk":275}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":86,"numAtRisk":273},{"groupId":"EG001","numAffected":100,"numAtRisk":275}]},{"term":"Periodontal disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":273},{"groupId":"EG001","numAffected":8,"numAtRisk":275}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":60,"numAtRisk":273},{"groupId":"EG001","numAffected":59,"numAtRisk":275}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":273},{"groupId":"EG001","numAffected":28,"numAtRisk":275}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":273},{"groupId":"EG001","numAffected":13,"numAtRisk":275}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":273},{"groupId":"EG001","numAffected":31,"numAtRisk":275}]},{"term":"Infusion site extravasation","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":72,"numAtRisk":273},{"groupId":"EG001","numAffected":78,"numAtRisk":275}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":273},{"groupId":"EG001","numAffected":13,"numAtRisk":275}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":5,"numAtRisk":275}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":64,"numAtRisk":273},{"groupId":"EG001","numAffected":41,"numAtRisk":275}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":273},{"groupId":"EG001","numAffected":9,"numAtRisk":275}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":273},{"groupId":"EG001","numAffected":8,"numAtRisk":275}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":273},{"groupId":"EG001","numAffected":6,"numAtRisk":275}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":273},{"groupId":"EG001","numAffected":9,"numAtRisk":275}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":4,"numAtRisk":275}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":273},{"groupId":"EG001","numAffected":19,"numAtRisk":275}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Periodontitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":273},{"groupId":"EG001","numAffected":9,"numAtRisk":275}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":273},{"groupId":"EG001","numAffected":13,"numAtRisk":275}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":273},{"groupId":"EG001","numAffected":6,"numAtRisk":275}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":273},{"groupId":"EG001","numAffected":18,"numAtRisk":275}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":273},{"groupId":"EG001","numAffected":10,"numAtRisk":275}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":273},{"groupId":"EG001","numAffected":6,"numAtRisk":275}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":273},{"groupId":"EG001","numAffected":35,"numAtRisk":275}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":273},{"groupId":"EG001","numAffected":0,"numAtRisk":275}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":273},{"groupId":"EG001","numAffected":28,"numAtRisk":275}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":273},{"groupId":"EG001","numAffected":12,"numAtRisk":275}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":8,"numAtRisk":275}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":273},{"groupId":"EG001","numAffected":10,"numAtRisk":275}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":273},{"groupId":"EG001","numAffected":18,"numAtRisk":275}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":273},{"groupId":"EG001","numAffected":11,"numAtRisk":275}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":273},{"groupId":"EG001","numAffected":9,"numAtRisk":275}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":117,"numAtRisk":273},{"groupId":"EG001","numAffected":141,"numAtRisk":275}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":62,"numAtRisk":273},{"groupId":"EG001","numAffected":67,"numAtRisk":275}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":273},{"groupId":"EG001","numAffected":16,"numAtRisk":275}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":94,"numAtRisk":273},{"groupId":"EG001","numAffected":99,"numAtRisk":275}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":98,"numAtRisk":273},{"groupId":"EG001","numAffected":108,"numAtRisk":275}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":273},{"groupId":"EG001","numAffected":8,"numAtRisk":275}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":273},{"groupId":"EG001","numAffected":3,"numAtRisk":275}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":273},{"groupId":"EG001","numAffected":14,"numAtRisk":275}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":273},{"groupId":"EG001","numAffected":11,"numAtRisk":275}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":273},{"groupId":"EG001","numAffected":15,"numAtRisk":275}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":273},{"groupId":"EG001","numAffected":11,"numAtRisk":275}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":273},{"groupId":"EG001","numAffected":19,"numAtRisk":275}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":72,"numAtRisk":273},{"groupId":"EG001","numAffected":84,"numAtRisk":275}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":273},{"groupId":"EG001","numAffected":19,"numAtRisk":275}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":3,"numAtRisk":275}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":273},{"groupId":"EG001","numAffected":6,"numAtRisk":275}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":273},{"groupId":"EG001","numAffected":10,"numAtRisk":275}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":76,"numAtRisk":273},{"groupId":"EG001","numAffected":92,"numAtRisk":275}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":273},{"groupId":"EG001","numAffected":16,"numAtRisk":275}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":273},{"groupId":"EG001","numAffected":21,"numAtRisk":275}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":273},{"groupId":"EG001","numAffected":20,"numAtRisk":275}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":273},{"groupId":"EG001","numAffected":28,"numAtRisk":275}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":273},{"groupId":"EG001","numAffected":12,"numAtRisk":275}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":59,"numAtRisk":273},{"groupId":"EG001","numAffected":64,"numAtRisk":275}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":273},{"groupId":"EG001","numAffected":18,"numAtRisk":275}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":121,"numAtRisk":273},{"groupId":"EG001","numAffected":116,"numAtRisk":275}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":45,"numAtRisk":273},{"groupId":"EG001","numAffected":49,"numAtRisk":275}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":273},{"groupId":"EG001","numAffected":6,"numAtRisk":275}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":67,"numAtRisk":273},{"groupId":"EG001","numAffected":74,"numAtRisk":275}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":273},{"groupId":"EG001","numAffected":34,"numAtRisk":275}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":273},{"groupId":"EG001","numAffected":13,"numAtRisk":275}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":273},{"groupId":"EG001","numAffected":48,"numAtRisk":275}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":273},{"groupId":"EG001","numAffected":12,"numAtRisk":275}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":45,"numAtRisk":273},{"groupId":"EG001","numAffected":36,"numAtRisk":275}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":273},{"groupId":"EG001","numAffected":13,"numAtRisk":275}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":273},{"groupId":"EG001","numAffected":6,"numAtRisk":275}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":273},{"groupId":"EG001","numAffected":11,"numAtRisk":275}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":273},{"groupId":"EG001","numAffected":16,"numAtRisk":275}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":143,"numAtRisk":273},{"groupId":"EG001","numAffected":150,"numAtRisk":275}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":273},{"groupId":"EG001","numAffected":17,"numAtRisk":275}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":1,"numAtRisk":275}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":273},{"groupId":"EG001","numAffected":24,"numAtRisk":275}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":273},{"groupId":"EG001","numAffected":3,"numAtRisk":275}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":61,"numAtRisk":273},{"groupId":"EG001","numAffected":48,"numAtRisk":275}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":96,"numAtRisk":273},{"groupId":"EG001","numAffected":48,"numAtRisk":275}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":273},{"groupId":"EG001","numAffected":14,"numAtRisk":275}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":273},{"groupId":"EG001","numAffected":7,"numAtRisk":275}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":74,"numAtRisk":273},{"groupId":"EG001","numAffected":89,"numAtRisk":275}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":9,"numAtRisk":275}]},{"term":"Vasculitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":273},{"groupId":"EG001","numAffected":11,"numAtRisk":275}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this tiral prior to submission for publication/presentation."},"pointOfContact":{"title":"Medical Information Center","organization":"Ono Pharmaceutical Co. Ltd","email":"clinical_trial@ono.co.jp","phone":"---"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-10-17","uploadDate":"2021-10-21T00:33","filename":"Prot_000.pdf","size":1633342},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-05-07","uploadDate":"2022-02-03T22:15","filename":"SAP_001.pdf","size":726842}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077594","term":"Nivolumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000068258","term":"Bevacizumab"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}